Drug Trial Radar · NCT02400255
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 2015
Primary completion
May 2022
Study completion May 2022
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation. Oral crenolanib will be administered daily post-transplant for up to two years.
Conditions
- Acute Myeloid Leukemia
Interventions
Crenolanib besylateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Who RelapsedTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.